Condition
ARB
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04367883Recruiting
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
NCT07185256Phase 1RecruitingPrimary
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
NCT04899206Withdrawn
ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA
Showing all 3 trials